Biotech Values

[poorgradstudent]

>As you pointed out,after pretty good 534 results the share price didn't appreciate too much and thats probably the after effect of Berger's dilutions and skepticism on the part of the investment community on the financial strength of the company as well as management competence. <

Why can't it be that they were phase I results, there is no pivotal trial running yet, and that approval is therefore a ways off?

I don't know if everyone is getting spoiled again by the market or what, but it seems there is a lot of complaining about why my stock X isn't constantly rising after a single good result in a small trial.